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Summary
Objective: To compare the response of knee and ankle cartilages to fibronectin fragments (Fn-f) in terms of kinetics of matrix proteoglycan
(PG) degradation and synthesis, since previous data had shown that knee was more sensitive to Fn-f in terms of steady-state PG content.
Design: Human knee and ankle cartilage explants were treated with the 29 kDa Fn-f, and its effects on PG-degradation kinetics, on the
half-lives of 35S-sulfate-labeled PG, on PG synthesis suppression and on matrix metalloproteinase -3 (MMP-3) were compared. Cultures
were also treated with the interleukin (IL) receptor antagonist protein (IRAP) in order to determine whether IL-1 is involved in the Fn-f effect.
Results: The Fn-f enhanced PG-degradation rates in both human knee and ankle cartilages. Knee cartilage showed a greater effect of Fn-f
on half-lives of newly synthesized 35S-labeled PG than ankle. The extent of release of MMP-3 was similar for human ankle and knee
cartilages. However, PG synthesis in knee cartilage was sensitive to 10- to 100-fold lower concentrations of Fn-f than was ankle cartilage.
IRAP partially reversed Fn-f activity in ankle cartilages.
Conclusions: The role of Fn-f in proteolysis leading to cartilage damage appears to be minor in human cartilages than had previously been
shown for bovine. This decreased proteolysis is true for both knee and ankle. The major difference between human ankle and knee cartilage
appears to be greater sensitivity to PG synthesis suppression in knee cartilage. A further indication that IL-1 is involved in the pathway was
provided by the partial reversal with IRAP.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Science Ltd. All rights reserved.
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Introduction
Studies have shown that human knee and ankle joints differ
in their prevalence of osteoarthritis (OA)1 or chondrodegen-
eration in vivo2. Our studies have focused on comparing
the cartilages from these two joints in order to determine
whether there are biochemical, biomechanical and/or
metabolic differences between the two cartilages, which
might help explain, in part, those differences in degener-
ation and disease progression. We have shown that syn-
theses of both the proteoglycan (PG)3 and the PG content4
of the ankle are higher than that of the knee. The higher PG
content along with lower water content results in differ-
ences in biomechanical properties, including higher equi-
librium modulus and dynamic stiffness, and lower hydraulic
permeability4.
Differences in the response of chondrocytes are also
evident between the two joint cartilages, especially with
respect to shifting the metabolic balance toward matrix
loss, either by decreasing matrix synthesis or increasing
matrix degradation. Exposure of chondrocytes to the in-
flammatory mediator interleukin (IL)-1β results in a cata-
bolic response of matrix loss. This involves both a decrease
in PG synthesis and an increase in proteolysis of PG. In
bovine chondrocytes, the predominant response is through
an increase in degradation, while human chondrocytes
respond to IL-1 with decreased matrix synthesis at low
doses; higher doses are required for increased proteolytic
activity. Our own data3 with human chondrocytes have
previously shown that there are differences in the sensitivity
of knee and ankle chondrocytes to their response to IL-1β.
Knee chondrocytes respond to lower doses of IL-1β (IC50
6.2 pg/ml) than do ankle chondrocytes (IC50 35 pg/ml).
With IL-1β stimulation, there is also an increase in proteo-
lytic activity in both the knee and ankle, as evidenced by
increased neoepitopes for both aggrecanase and matrix
metalloproteinases (MMPs); the levels of neoepitopes were
higher in the knee than in the ankle. The ankle is also able
to rebound faster with increased PG synthesis than the
knee, when IL-1β is removed.
There are also significant differences between the knee
and ankle chondrocyte response to fibronectin fragments
(Fn-f)5. The 29 kDa Fn-f caused a greater degree of
PG loss (30–50%) from knee cartilage than from ankle
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cartilage in explant culture; this loss occurred within 7 days
in the knee, while PG loss was less evident and less
consistent in the ankle even after 28 days of culture.
Although we were able to show that there was an increased
proteinase activity in the knee indicative of activation of PG
degradation, the loss of PG could have occurred by depres-
sion of PG synthesis as well, since the 29 kDa fragment is
capable of modulating both activities6,7. The Fn-f increases
levels of catabolic cytokines including IL-1, levels of MMPs
and aggrecanase and the rapid loss of PG from both bovine
and human cartilage explants8–10. The fragments are
thought to, at least partially, work through a common
pathway with IL, since both enhanced matrix MMP-3 re-
lease from the cartilage and PG synthesis suppression can
be partially reversed by addition of neutralizing anti-IL-β
antibodies9–11. The Fn-f has also been previously shown to
inhibit PG synthesis in both bovine and human cartilages12.
The 29 kDa Fn-f model is physiologically relevant to
address the question of mechanisms that might explain the
differences in PG loss (reviewed in references 13 and 14).
The Fn-f is elevated in OA synovial fluid and cartilage and
can be generated by the addition of MMP-3 or catabolic
cytokines15,16. Intra-articular injection of Fn-f into rabbit
knees causes severe cartilage matrix damage17. In an
in vitro explant model, the cartilage responds with many
elements in common with damaged or OA cartilage14,18.
Our initial studies showed differences between knee and
ankle cartilages that were based on Fn-f-mediated PG
depletion of the knee cartilage, while the ankle appeared to
be unaffected5. In the current study, we have attempted to
dissect out the pathways that contribute to or compensate
for PG depletion by comparing PG-degradation kinetics
measured as PG release from the cartilage, PG half-lives,
PG synthesis suppression as well as the contributions of
MMP-3 and IL-1 to the pathway. Our results show that the
Fn-f affects not only the knee, but also the ankle. Both
involve a relatively small proteolytic component compared
with a large PG synthesis suppression component. The
major difference between ankle and knee chondrocyte
sensitivities to Fn-f appears to be a decreased sensitivity of
ankle cartilage to PG synthesis suppression and not an
increased sensitivity of knee cartilage to PG degradation.
Materials and methods
All chemicals were from Sigma (St. Louis, MO) except as
otherwise noted. The 29-kDa Fn-f was generated from
human plasma fibronectin as previously described8 and is
denoted here simply as Fn-f. IL receptor antagonist protein
(IRAP) and the MMP-3 ELISA Kit were from R&D systems
(Minneapolis, MN). The 35S-sulfate was purchased from
ICN Biomedicals, Inc. (Cosa Mesa, CA).
CARTILAGE SOURCES
Cartilages were obtained from 31 donors through the Gift
of Hope Organ and Tissue Donor Network within 24 h
postmortem according to their protocol, and with approval
of the Institutional Review Board. The donors ranged in age
from 15 to 90 years, with an average age of 59.7 years.
Cartilages from 21 men and 10 women were included in
the study. Ankle cartilages were removed from the dome
of 19 tali, and knee cartilages from 16 femoral condyles.
The joints were graded according to the macroscopic
assessment scale published by Collins19 as modified by
Muehleman et al.20.
TISSUE CULTURE
Cultures of knee and ankle cartilage explants (60–
100 mg per explant) were established as previously de-
scribed5,10. The explants were taken from full-thickness,
uncalcified cartilages, and cultured at 37°C in air with 5%
CO2 in 24-well plates containing 1.5 ml Dulbecco’s modi-
fied Eagle medium, 50 U/ml each of penicillin and strepto-
mycin. For all experiments, the explants were allowed to
equilibrate for 2 days prior to the addition of test com-
pounds. Each datum was a mean±SD based on at least
three tissue culture wells.
MEASUREMENT OF KINETICS OF PG DEGRADATION
After 2 days of equilibration, Fn-f (1 µM) was added, and
cultures were continued for 7–14 days. Controls were
identical except that no Fn-f was added. An aliquot of media
was taken from each well every other day and frozen at
−20°C until assayed. The cartilage explants were weighed
at the end of the experiment. PG content of the conditioned
media was determined by a dimethylmethylene blue
(DMMB) dye-binding assay10. The data were calculated as
µg PG/mg wet-weight cartilage, graphed vs days, and
subjected to linear regression to obtain slopes that are
reported as PG-degradation rates of µg PG/mg wet-weight
cartilage/day.
MEASUREMENTS OF THE HALF-LIVES OF 35S-LABELED PG
Changes in the half-life of 35S-labeled PG were used as
another index of PG degradation21. Briefly, sodium 35S-
sulfate (6 µCi/ml) was added to the media for 48 h. The
cartilage explants were washed and allowed to equilibrate
for 24 h in the absence of label and then treated with 1 µM
Fn-f; control cultures were identical except that no Fn-f
were added. The cultures were continued for 30 days. An
aliquot of media was removed daily and counted to deter-
mine isotope release. The values were normalized for
radioisotope decay and converted into percentage of total
label value. Graphs of log percentage of remaining label vs
days were subjected to linear regression analyses to obtain
slopes from which the half-lives were calculated.
MEASUREMENT OF TOTAL MMP-3 LEVEL BY ELISA
The total MMP-3 (pro and active) in the conditioned
media from the knee and ankle articular cartilages was
measured by a MMP-3 ELISA according to manufacturer’s
instructions. Briefly, conditioned media was collected on
days 3 and 7 and stored at −20°C until assayed. A 100 µl of
assay diluent RD1-52 was added to each well of a 96-well
ELISA plate. The conditioned media (100 µl of samples
diluted 1:1000 and 1:10 000) and serially diluted MMP-3
standard protein were added to the corresponding wells.
The plate was covered and incubated at room temperature
for 1.5 h. The wells were washed, and 200 µl of MMP-3
conjugate were added to each well. The plate was covered
and incubated for 2 h at room temperature. The wells were
washed, and 200 µl of the substrate solution was added.
After 30 min at room temperature, the reaction was
stopped and the plate was read at 450 nm within 30 min.
MEASUREMENT OF PG SYNTHESIS
Sulfate incorporation was used as an index of synthesis
of sulfated PG as previously described with some modifi-
cations22,23. Fn-f were added at concentrations from
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0.1 mM to 1 µM. PG synthesis was measured using a 4-h
pulse with 6 µCi/ml of 35S-sodium sulfate. The cartilage
explants were washed, weighed and digested with papain
(200 µg/ml papain in 0.1 M NaH2PO4, pH 6.0, 5 mM EDTA,
5 mM cysteine HCl) for 18 h at 65°C. The papain digests
were dialyzed against 10 mM EDTA–water and then
subjected to scintillation counting.
THE EFFECTS OF IRAP
IRAP (1 µg/ml) was added to human ankle cultures for
4 h before 1 µM Fn-f was added. PG synthesis for each
sample was assayed on day 2 by a 4-h pulse with 6 µCi/ml
of 35S-sodium sulfate. The cartilage explants were ex-
tracted with 1 ml of 4 M GuHCl, 10 mM EDTA, pH 5.5 for
16 h and dialyzed against water and then subjected to
scintillation counting. The amount of label was expressed
as dpm/mg wet-weight cartilage.
STATISTICAL ANALYSIS
Unpaired Student’s t-test analysis was used to test
whether there were effects of Fn-f on individual donor
cartilages, because although each experiment was based
on cartilage obtained from an individual donor, we could
not ignore the possibility of cartilage heterogeneity from
well-to-well and differential effects of the Fn-f. When data
were combined, unpaired analysis was also used based on
the observation that there was donor-to-donor variability.
A P value <0.05 was considered to be significant.
Results
KINETICS OF PG DEGRADATION
A concentration of 1 µM 29-kDa Fn-f was used through-
out these studies, based on our observation of µM concen-
trations of Fn-f in human OA synovial fluid16. At this
concentration, we have shown that Fn-f very significantly
increase rates of PG degradation of bovine cartilage in
serum-free cultures8. Degradation rates were calculated as
the slope of µg PG released per mg wet-weight cartilage,
as shown for one representative knee sample in Fig. 1.
When the release rates for controls, cultured without Fn-f
with explants from 11 different knee and ankle donor
cartilages, were calculated, the rates were similar (Table I).
With Fn-f stimulation, the rates increased significantly; for
the knee, the rate was 1.5-fold that of control and for the
ankle, the rate was 1.3-fold that of control. These data were
surprising, since we had expected the degradation rate to
be higher in the knee based on our previous study5 that had
shown significant decreases in PG content of the knee, but
not the ankle cartilage. This observation of no significant
differences between ankle and knee cartilages suggested
that another parameter was responsible, such as a greater
PG synthesis suppression in knee than ankle, which would
have the effect of decreasing the ability of knee cartilage to
compensate for the normal turnover of matrix PG. It is
interesting that the rates, in Table I, of less than 0.7 are far
lower than the rates of 5.7 that we have reported in bovine
cartilage in the presence of Fn-f8. Thus, human cartilage
demonstrates far lower rates of PG degradation than
bovine cartilage.
Fig. 1. PG release into media was measured by the DMMB assay and normalized to the wet weight of the explant at the end of 7 days of
culture. The graph is the data from the culture of knee cartilage from a 71-year old man, and is shown as a representative sample of one
of the 11 different knee donor cartilages that were used to determine the degradation rates. For this knee cartilage, the control degradation
rate was 0.367±0.005 µg PG/mg cartilage, and for Fn-f-treated the rate was 0.449±0.015 µg PG/mg cartilage. The P value was 0.003.
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HALF-LIVES OF 35S-LABELED PG
The measurements of PG half-lives may provide a more
sensitive measure of degradation than would the measure-
ment of PG-degradation kinetics, since the former meas-
ures a smaller pool than the latter. In order to compare the
turnover of a more specific pool of PG in the knee and
ankle, the chondrocytes were exposed to 35S-sulfate for
48 h to label newly synthesized PG. Cultures were then
continued for 30 days and the half-lives of the PGs were
determined. In the controls without Fn-f, the half-life in the
ankle was slightly shorter than that in the knee, but the
difference did not reach significance. When the Fn-f were
added, newly synthesized 35S-labeled PG half-lives of both
human knee and ankle cartilages decreased significantly
(Fig. 2; Table II). Figure 2 shows a representative set of
data from a single donor. When the data from three donors
were averaged, Fn-f decreased the half-life of newly
synthesized 35S-labeled PG of human knee cartilage sig-
nificantly by an average of 1.87-fold, compared with control
cartilage. In comparison, in ankle cartilage, the Fn-f de-
creased the half-life of 35S-labeled PG significantly com-
pared with control cartilage by 2.36-fold. The differences
between ankle and knee cartilage were not significant
(P0.15). The effect on half-lives in Fn-f-treated bovine
cartilage was reported by us to be nearly a 5-fold
decrease24, or nearly double that for ankle and knee
cartilages, suggesting a greater sensitivity for bovine
cartilage.
MEASUREMENT OF TOTAL MMP-3 LEVEL BY ELISA
Since MMP-3 is a major MMP responsible for Fn-f-
mediated PG degradation11 and since it can be used as a
correlate of cytokine activity10, we investigated whether the
levels released from the cartilage would be greater in knee
than in ankle. Fn-f significantly increased MMP-3 levels in
both human knee and ankle cartilages (Table III). After 3
days of treatment with Fn-f, there was no significant differ-
ence in total MMP-3 levels between the Fn-f-treated and
control knee cartilage. However, for the human ankle
cartilage, there was a significant difference of 5.7-fold in
the MMP-3 levels between the Fn-f-treated and control
(two-tailed P0.0081). After a 7-day treatment, the differ-
ence in total MMP-3 levels between the Fn-f-treated
and control knee cartilage was significant by 4.7-fold. In
comparison, the difference between Fn-f-treated and con-
trol ankle cartilage was also significantly increased by
8.3-fold. When comparing the day-7 Fn-f-treated total
MMP-3 levels between knee and ankle cartilages, the
MMP-3 concentration is about 1.29-fold higher in ankle
cartilage-conditioned media than that in knee cartilage-
conditioned media (two-tailed P0.0498). This difference is
Table I
The effect of 1 µM Fn-f on PG-degradation rates
Sample Control* Fn-f* P value
Knee 0.44±0.13 0.68±0.28 0.0098
Ankle 0.44±0.11 0.58±0.14 0.012
PG released into the media during 7 days of culture was
determined by the DMMB assay and expressed as µg PG/mg
wet-weight cartilage based on a mean and SD from triplicate wells
for each different cartilage explant. The PG release per mg
wet-weight cartilage was then graphed vs days, and data were
subjected to linear regression to obtain slopes. The slopes are
reported as PG-degradation rates of µg PG/mg wet-weight
cartilage/day. Explants from 11 different ankle donors and 11 knee
donors were used to obtain the data.
*µg PG/mg cartilage/day.
Fig. 2. Half-lives of 35S-labeled PG knee (A) and ankle (B) explants
were labeled with 6 µCi/ml 35S-sulfate for 48 h and then equili-
brated for 24 h in the absence of label. The cartilage explants were
incubated with or without 1 µM Fn-f. An aliquot of the media was
taken from each well every day and subjected to scintillation
counting. The amount of label was expressed as cpm/mg wet-
weight tissue and normalized for radioactive decay and converted
into percentage of total counts. The data were transformed to
logarithmic form and calculated as log (percentage of 35S-labeled
PG content). Each data point is based on mean and SD of three
separate culture wells. The log (percentage of 35S-labeled PG
content) was then graphed vs days and data were subjected to
linear regression and extrapolated to the X-axis. The X intercept
at Y=1.7 was used to obtain apparent half-lives and SD values
(N3).
Table II
Half-lives of 35S-labeled PG of knee and ankle
Sample Control* Fn-f* P value
Knee 22.68±2.73 12.1±1.42 0.002
Ankle 16.58±5.23 7.02±3.51 0.029
The mean and SD were based on triplicate explants from three
different knees and three ankle donors.
*Days.
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barely significant and does not explain why human knee
cartilage PG is more easily depleted than ankle cartilage
PG as previously reported5.
PG SYNTHESIS SUPPRESSION
Since the parameters of PG-degradation kinetics and PG
half-lives did not show significant differences between
ankle and knee, we next tested whether differences in
Fn-f-mediated PG synthesis suppression might explain
differences. We tested the dose response effect of the Fn-f
with concentrations between 0.1 nM and 1 µM. Fn-f-
mediated PG synthesis suppression in ankle cartilage
required up to a 100-fold higher concentration of Fn-f than
the PG synthesis in knee cartilage (Figs. 3 and 4). The
dose response curves of four knee cartilages from four
different donors are shown in Fig. 3. For all four knee
cartilages, Fn-f as low as 1 nM significantly suppressed PG
synthesis, with the percentage inhibition at 1 nM Fn-f
varying from 14.6 to 22.1% for three of the cartilages. In the
fourth cartilage, 10 nM Fn-f was required for a 15.4%
inhibition. At 1 µM Fn-f, inhibition was as high as 44–66%.
The general effects of the Fn-f on human knee cartilage
were similar to the effects on bovine cartilage, where 1 nM
Fn-f had significant effects on PG synthesis and 1 µM
suppressed up to 50% in serum-free cultures8, similar to
the conditions studied in this study, while in 10% serum
cultures, higher concentrations on the order of 10 nM were
required for significant effects with 50% suppression also
occurring at 1 µM7. In contrast, PG synthesis suppression
in ankle cartilages required higher concentrations of Fn-f
(Fig. 4). For four ankle cartilages, a concentration as high
as 100 nM Fn-f was required for a significant effect of
18.4–29%. The inhibition at 1 µM Fn-f ranged from 38 to
50%. We have also reported that bovine cartilage typically
shows a maximal PG synthesis suppression effect of
50%7,12,23. Therefore, since this may be the limit of the
effect, it was more appropriate to compare the minimal
threshold of the effect rather than the maximal effect. These
data further support that Fn-f predominantly affect human
cartilage by suppression of PG synthesis and not enhance-
ment of PG degradation.
THE EFFECTS OF IRAP
Since our previous studies9 with the Fn-f had shown that
IL-1 was involved in the degradative pathway, we, there-
fore, asked whether the IRAP could partially reverse the
effects of the Fn-f. IRAP was able to significantly reverse
Fn-f activity on PG synthesis at both 100 ng/ml and 1 µg/ml
(one-tailed P0.048 and 0.012, respectively) (Fig. 5). The
Fn-f suppressed cartilage PG synthesis significantly in
three donors (P0.0035, 0.002 and 0.034, respectively).
The 1 µg/ml IRAP treatment significantly reversed the Fn-f
activity in the two of the three donors (P0.012, 0.015 and
0.251, respectively). The percentage of reversal was 77
and 62%, respectively, for the first two donors. These
results suggest that IL-1 may be involved in Fn-f-mediated
PG synthesis suppression of human ankle cartilage. We
did not report on the effects on PG degradation, since the
rates were too low for us to accurately assess the effects.
Discussion
The primary objective of this study was to compare the
differential effects of Fn-f on human knee and ankle carti-
lage PG degradation and synthesis. A second objective
was to also compare, where possible, the human data with
bovine data. Much more work has been published on the
effects of Fn-f on bovine cartilage. The reason for this
second objective was to provide information on the possi-
ble differential sensitivities of different species to the effects
of Fn-f. This point is especially important as different culture
systems are used to investigate Fn-f activities, and this may
lead to erroneous conclusions.
In this study, the explant culture was used in order to
maintain the native state chondrocyte–matrix interactions
and to compare the results of this study with our previously
reported comparison. Our earlier studies7,12,15,18,23 have
shown that in bovine and human cartilages, Fn-f exerted
several catabolic activities: stimulation of PG degradation,
temporary suppression of PG synthesis and MMP-3 induc-
tion. However, since measurement of PG content reflects
steady-state levels and the contributions of both anabolism
and catabolism, the previous studies could not be used to
provide an explanation for differences that were observed
between the ankle and knee cartilages. For the current
study, we have separately compared kinetic aspects of PG
degradation and PG synthesis suppression in order to
determine whether the differential effects of Fn-f on human
knee cartilage were due to effects on catabolic aspects
only, or anabolic aspects only, or both.
We found that both knee and ankle cartilages showed
significantly increased PG-degradation rates in response to
Fn-f treatment (1.54- and 1.3-fold); surprisingly, there did
not appear to be a significant difference between the two,
as we had expected. In comparison, we have reported that
the rates increase nearly 5-fold in bovine cartilage, sug-
gesting a greater proteolytic component8. Since there are
different pools of PG in the cartilage25,26, PG-degradation
rates would include PG released from the entire cartilage
not only in the cell-associated matrix, but also in territorial
and interterritorial matrix. Therefore, we attempted to use a
more sensitive and specific method to explore differences,
namely, examining whether the newly synthesized pool of
PG shows differential turnover when ankle and knee carti-
lages are compared. Our results showed that there were
1.87- and 2.36-fold differences between the half-life of the
Fn-f-treated and control 35S-labeled PG of human knee
and ankle cartilage, respectively. Nonetheless, these find-
ings suggest that this pool of PG may not significantly
contribute to any potential differential PG loss from human
knee and ankle cartilages. Therefore, the results suggest
that Fn-f enhance turnover of newly synthesized PG to the
Table III
Effect of 1 µM Fn-f treatment on the knee and ankle MMP-3
release
Sample Total MMP-3 release P value
Control Fn-f
Day 3
Knee 0.83±0.337 4.85±3.23 0.165
Ankle 0.71±0.095 4.05±0.51 0.0081
Day 7
Knee 16.6±8.24 78.15±12.12 0.0019
Ankle 12.13±1.89 100.76±7.18 <0.0001
The data from three knees and three ankle cartilages were
calculated as ng total MMP-3/mg tissue wet-weight and are given
as mean±SD. P values were determined by comparison with
control using the unpaired two-tailed Student’s t-test.
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same degree. Thus, a differential turnover of newly synthe-
sized PG cannot explain the greater susceptibility of knee
cartilage to Fn-f-mediated PG depletion as compared with
effects on ankle cartilage.
We also tested as another catabolic parameter, whether
Fn-f differently enhanced MMP-3 levels in ankle and knee
cartilages. We had shown earlier that Fn-f enhanced
MMP-3 release from human knee cartilage in 10% serum
with a peak at about 7 days and with about half as much
release by day 310. With the serum-free culture conditions
studied here, the release was much lower at day 3 than
would be expected. We have no explanation for this differ-
ence except for the difference in culture conditions. None-
theless, it appeared that the MMP-3 level by day 7 was
relatively higher in ankle than in knee cartilage-conditioned
media in the presence of Fn-f. If we assume that the
MMP-3 was fully activated, as we have previously shown in
human explants11, this result is consistent with the devel-
oping notion that differences in catabolic parameters do not
account for the ankle vs knee differences. Since MMP-3 is
upregulated by catabolic cytokines, this result is also con-
sistent with the possibility that the cytokine responses do
not greatly differ in ankle vs knee cartilages in the presence
of Fn-f. However, since aggrecanase activity is also in-
volved in Fn-f-mediated matrix degradation5,18,27, it is
possible that there may be differences in levels of this
proteinase as well as other MMPs. Since our laboratory
has published that the aggrecanase-generated NITEGE
neoepitope surrounding chondrocytes stimulated with Fn-f
can be detected in knee cartilage, but not ankle cartilage5,
these results are consistent.
After examination of the several parameters involved in
PG degradation, we considered that differences in PG
synthesis suppression in ankle vs knee cartilage by Fn-f
may be responsible for differences in PG depletion.
While both knee and ankle cartilages dose dependently
Fig. 3. Dose response of the Fn-f on knee cartilage PG synthesis. Fn-f were added at concentrations from 0.1 nM to 1 µM. After 2 days, PG
synthesis was measured using a 4-h pulse with 6 µCi/ml of 35S-sodium sulfate. The tissue explants were then papain-digested, and the
digests were dialyzed. The label was quantified. Data are the mean±SD of three similar wells in each experiment (N3). The P values were
obtained when compared with control using the unpaired one-tailed Student’s t-test. (A–D) Results from the cultures of knee cartilages from
four different donors (*P<0.05, **P<0.01, ***P<0.001).
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responded to the Fn-f treatment, the threshold of Fn-f
concentration needed for significant knee cartilage re-
sponses was typically much lower than for ankle cartilage,
frequently by a factor of 100-fold. These results collectively
suggest that Fn-f-mediated PG synthesis suppression
likely plays a major role in differential PG depletion between
knee and ankle cartilages.
It was interesting to note that the effective concentration
range of Fn-f on knee PG synthesis was similar to the
range we have reported for bovine cartilage8, suggesting
that while bovine cartilage shows a greater proteolytic
profile in the presence of Fn-f than does knee cartilage
(8-fold higher), the ability of both types of tissue to replace
PG in the presence of Fn-f are equally compromised. Thus,
one can question why bovine cartilage with the greater
proteolytic profile (PG-degradation rates) does not show far
greater extents of PG depletion than does human knee
cartilage. In fact, both show extents of PG depletion in the
range of 40–50% in 7-day cultures5,23. The explanation
may be that the rates of PG synthesis in bovine cartilage
are higher than in human knee cartilage, and higher by the
same fold as the differences in proteolytic activity. We did
not compare bovine and human cartilages in terms of
absolute rates of PG synthesis, so we cannot yet reach that
conclusion.
As a secondary objective, we attempted to obtain ad-
ditional confirmation of the role of catabolic cytokines in
Fn-f-mediated activities. We have reported that neutralizing
antibodies to various catabolic cytokines partially reverse
MMP-3 release and PG synthesis suppression in human
chondrocyte cultures9,10. We, therefore, tested for the
neutralization of Fn-F-mediated PG suppression by IRAP
and found that IRAP was partially effective at 100 ng/ml in
reversing Fn-f-mediated PG synthesis suppression. These
data suggest that IL-1 is involved in PG synthesis suppres-
sion. The reversal may not have been complete because
Fig. 4. Dose response of the Fn-f on ankle cartilage PG synthesis. The method was the same as described in Fig. 3. Data represent the
mean±SD of triplicate sample wells in each experiment. The P values were obtained when compared with control using the unpaired
one-tailed Student’s t-test. (A–D) Cultures of ankle cartilages from four different donors (*P<0.05, **P<0.01).
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Fn-f also enhance release of IL-6 and tumor necrosis factor
(TNF-α)9,10, factors that play an active role in Fn-f activity9.
Our work here demonstrates an active role for IL-1 in the
effects on human cartilage in that IRAP-decreased Fn-f
activity. We had shown earlier that neutralizing antibodies
to IL-1α, IL-1β, IL-6 and TNF-α decrease Fn-f activities9.
Others have demonstrated that IRAP decreased induction
of MMP-3 and MMP-13 by a heparin-binding Fn-f28, or
partially blocked NO release from human chondrocytes
treated with an N-terminal 29-kDa Fn-f29, or blocked MMP-
1-induced release by an extra domain A fibronectin pep-
tide30, or decreased MMP-3 upregulation by an RGDS
peptide found in the fibronectin cell-binding domain31, or
blocked activation of MMP-13 in human chondrocytes by a
120-kD cell-binding Fn-f32. However, there are reports that
IRAP failed to block upregulation of MMP-3 and MMP-13 in
chondrocytes by a 45-kDa gelatin-binding fragment33 or
failed to block upregulation of MMP-13 by 120-kDa Fn-f
added to human chondrocytes32. These differences may
reflect differences in potencies of IRAP, or different cell
culture systems, or different species of cartilage. It should
be noted that in studies where IRAP is tested, the ability of
IRAP to block exogenous IL-1 is often used as a control.
Yet, there is no information on the relative concentration of
induced IL-1 around the chondrocyte, which may be much
higher than that added for a positive control. It may be very
difficult to block de novo induced IL-1 vs added IL-1, which
becomes diluted as it penetrates the cartilage. Further, we
do have evidence for other cytokines in other Fn-f system
and since cytokine networks often involved cross-
upregulation of one cytokine by another; complete inhi-
bition of IL-1 by IRAP may not be possible under every
culture condition.
The reason for these differences in effects of the Fn-f on
ankle vs knee cartilage may be multiple and include differ-
ences in penetration of the Fn-f, in cytokine protein levels,
in cytokine receptors, of cytokine signaling, to name a few.
We are currently investigating these possibilities. As pre-
sented in the Introduction section, other data suggest a
greater sensitivity of knee cartilage to cytokines and a
lesser rebound potential after cytokine treatment as com-
pared with ankle cartilage3. Further, ankle chondrocytes
appear to be more synthetically active3. Thus, while differ-
ences in penetration may be possible, there are likely many
other explanations. We think penetration differences are
unlikely because, as we have shown in this study, the
extents of PG synthesis suppression are similar for both
ankle and knee.
Taken together, these results demonstrate that Fn-f
exerts differential catabolic effects on knee and ankle
Fig. 5. Effect of IRAP on Fn-f-mediated ankle cartilage PG synthesis. IRAP (1 µg/ml) was added for 4 h before 1 µM Fn-f was added to the
culture. Cultures were continued for 48 h, and the PG synthesis was assayed by 4-h pulse with 35S-sodium sulfate. Data represent the
mean±SD from triplicate wells. The P values were obtained using the unpaired Student’s t-test. (A–C) Results from three different donors.
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cartilages. The Fn-f-mediated PG synthesis suppression
likely plays a major role in different susceptibility of the
cartilages to PG depletion. In the human tissue, the in-
creased protease activity may play more of a minor role.
These results also confirm that the cytokine, IL-1, is likely to
be involved in Fn-f catabolic activity on human cartilage.
Since cytokines are likely involved in suppression of PG
synthesis, the observation that ankle and knee cartilages
display differences in PG synthesis suppression by Fn-f
suggests that more complicated explanations are required
to explain these differences. The Fn-f model of cartilage
damage should be quite useful for continued investigation
of differences in susceptibility to damage.
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